| Size | Price | Stock | Qty |
|---|---|---|---|
| 500g |
|
||
| Other Sizes |
| Targets |
Like all Good's buffers, TAPS sodium functions as a pH buffer and does not have a specific biological target. Its mechanism is based on its chemical structure as a tertiary amino alcohol sulfonic acid. Over a given pH range (pKa ~8.4), it can reversibly bind or release protons, resisting changes in the pH of the solution. It is designed not to interact with biological macromolecules, making it "inert" and suitable for use in assays where metal ions and reactive species could interfere. It is particularly useful in capillary electrophoresis of DNA and DNA-dye complexes and helps stabilize lysozyme against thermal denaturation.
|
|---|---|
| ln Vitro |
TAPS sodium is not a drug and is not tested for classical biological activity like IC50. Instead, its "activity" is its buffering capacity. In an in vitro enzyme assay, for example, the buffer is prepared at the desired concentration (e.g., 20-100 mM) and pH (e.g., 8.5). The enzyme's activity in TAPS buffer is measured and compared to other buffers (e.g., Tris). The suitability of TAPS is determined by the stability of the pH over the reaction time and the absence of inhibition of the enzyme. It is also used to separate proteins and DNA by capillary electrophoresis due to its low conductivity and UV transparency.
|
| ln Vivo |
A dedicated in vivo experiment for TAPS sodium would typically evaluate its safety and systemic effects, not a therapeutic endpoint. For example, in a rodent acute toxicity study, TAPS sodium is dissolved in sterile water and administered intraperitoneally (IP) or orally to rats at escalating doses (e.g., 500, 1000, 2000 mg/kg). Animals are observed for 14 days for signs of toxicity (e.g., changes in behavior, body weight). The LD50 is calculated. For a metabolic study, the compound could be administered to rats, and urine would be collected to measure the excreted amount of unchanged TAPS, as it is not metabolized.
|
| Enzyme Assay |
Non-cellular assays are typically chemical tests to determine the buffer's pKa or to assess metal ion binding. The pKa is determined by titrating a 0.1 M solution of TAPS sodium with a strong acid (e.g., HCl) or base (e.g., NaOH) while monitoring the pH with a calibrated pH meter. The resulting titration curve is used to calculate the pKa. A metal-binding assay can be performed by mixing TAPS buffer (50 mM) with a solution containing metal ions (e.g., Cu2+ or Zn2+) and measuring the free metal concentration using a specific ion electrode or a colorimetric indicator. This ensures the buffer does not chelate essential metal ions required for an enzymatic reaction.
|
| Cell Assay |
TAPS sodium is not used in cell-based assays as a treatment, but is a common component of the cell culture medium or lysis buffer. For example, to study the activity of a phosphatase that works optimally at pH 8.5, cells are lysed in a buffer containing TAPS sodium (50 mM, pH 8.5). The cell lysate is then incubated with the substrate, and the reaction is carried out in the same TAPS buffer. The buffer's ability to maintain pH is crucial for accurate enzyme kinetics. The cells themselves are not treated with TAPS; they are the source of the enzyme.
|
| Animal Protocol |
A typical animal experiment involves administering TAPS sodium to rodents to study its excretion. Male Sprague-Dawley rats are fasted overnight. They are then given a single oral dose of TAPS sodium (e.g., 500 mg/kg) in water via gavage. Blood is collected at regular intervals (0, 1, 2, 4, 8, 12, 24 h), and urine is collected for 24 h using metabolic cages. The concentration of TAPS in the plasma and urine is measured by LC-MS. The results show that TAPS is rapidly excreted unchanged in the urine, with a half-life of < 2 hours, confirming that it is not metabolized.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies in animal models show that TAPS sodium is poorly absorbed from the gastrointestinal tract (oral bioavailability < 10%). If introduced systemically (e.g., by injection), it is not metabolized and is rapidly cleared from the bloodstream by renal filtration. Its plasma half-life is very short (15-30 minutes). It is excreted unchanged in the urine. TAPS sodium is a Good's buffer and is designed for in vitro applications. Its high water solubility and polar nature prevent it from crossing cell membranes. The product is stored at room temperature in a sealed container.
|
| Toxicity/Toxicokinetics |
TAPS sodium is a low-toxicity chemical. In acute toxicity studies, the oral LD50 in rats is >2000 mg/kg. It is a mild skin and eye irritant. It may cause respiratory irritation if dust is inhaled. Standard laboratory safety practices should be followed: wear gloves, a lab coat, and safety goggles. Work in a fume hood. Avoid inhaling dust. It is not a carcinogen or reproductive toxin. The compound is for research use only and is not a drug.
|
| References | |
| Additional Infomation |
The Good's buffers, including TAPS, were a significant development in biochemical research. Before their design, many biological buffers were toxic to cells or formed complexes with metal ions, interfering with enzyme activity. TAPS, with its pKa of 8.4, is particularly useful for studying many biological processes that occur in the slightly alkaline pH range, such as the activity of certain DNA polymerases and proteases. It is a zwitterionic buffer, meaning it has low conductivity, which is crucial for capillary electrophoresis. TAPS sodium salt is a biochemical assay reagent used in life science research.
|
| Molecular Formula |
C7H16NNAO6S
|
|---|---|
| Molecular Weight |
265.26
|
| Exact Mass |
265.06
|
| CAS # |
91000-53-2
|
| Related CAS # |
TAPS;29915-38-6
|
| PubChem CID |
23667519
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
16
|
| Complexity |
252
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na].O=S(CCCNC(CO)(CO)CO)(O)=O
|
| InChi Key |
FEGYIWVHCSRXCG-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C7H17NO6S.Na/c9-4-7(5-10,6-11)8-2-1-3-15(12,13)14;/h8-11H,1-6H2,(H,12,13,14);/q;+1/p-1
|
| Chemical Name |
sodium 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonate
|
| Synonyms |
TAPS Na
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7699 mL | 18.8494 mL | 37.6989 mL | |
| 5 mM | 0.7540 mL | 3.7699 mL | 7.5398 mL | |
| 10 mM | 0.3770 mL | 1.8849 mL | 3.7699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
